{"id":"W4406679883","doi":"10.1038/s41591-024-03415-7","title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":114,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Breast cancer; Internal medicine; Oncology; Epirubicin; Placebo; Chemotherapy; Population; Docetaxel; Neoadjuvant therapy; Cyclophosphamide; Cancer; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002212056,0.001331382,0.002083517,0.0003556208,0.0004468149,0.0009735429,0.0007271646,0.001468025,0.00505714],"category_scores_gemma":[0.001466212,0.0006344713,0.001700002,0.0004134018,0.0009647603,0.0007449797,0.0003329501,0.002274964,0.000691623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000778948,"about_ca_system_score_gemma":0.001442189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001048292,"about_ca_topic_score_gemma":0.002147367,"domain_scores_codex":[0.9993201,0.000422646,0.00003830344,0.00009482183,0.00004319867,0.00008076856],"domain_scores_gemma":[0.999285,0.0002038452,0.0001632194,0.00005743431,0.00004372511,0.0002467454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9816552,0.006468308,0.0003962175,0.0003534206,0.0004945965,0.00002870784,0.00002836062,0.0001981606,0.002425219,0.00006923584,0.0004927552,0.007389833],"study_design_scores_gemma":[0.9579026,0.03993193,0.001027935,0.0000214107,0.0002784755,0.00001584857,0.000009194342,0.0002394225,0.0002056473,0.00006944183,0.0002910471,0.00000704161],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852875,0.004319871,0.0006059136,0.0007588936,0.0005171574,0.00599746,0.0007960422,0.0000867684,0.001630397],"genre_scores_gemma":[0.9844892,0.002609777,0.001367729,0.001324203,0.0003983528,0.007024475,0.000804884,0.00001768126,0.001963755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00505714,"threshold_uncertainty_score":0.01691777,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.003714202626114731,"score_gpt":0.3019830404053858,"score_spread":0.298268837779271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}